Blog

A 2025 multi-centre validation study has demonstrated that AI-assisted ultrasound analysis significantly improves the early detection of fetal growth restriction compared to standard manual biometry assessment alone, identifying at-risk pregnancies an average of 1.5 to 2 weeks earlier — a window that can meaningfully change clinical management and outcomes. As Dubai continues to position itself as a regional hub for advanced medical technology adoption, developments like this AI-assisted ultrasound research are of particular interest to the city’s growing network of specialist obstetric and fetal medicine providers, who frequently look to integrate validated new technologies ahead of broader regional uptake. What Fetal Growth Restriction Is and Why Early Detection Matters Fetal growth restriction occurs when a baby does not grow at the expected rate in the womb, most commonly due to placental insufficiency. Early detection allows for closer monitoring, optimised timing of delivery, and in some cases, interventions that can improve outcomes — but growth restriction can be subtle and easily missed using standard measurement techniques, particularly in its earlier stages. How AI-Assisted Ultrasound Works The technology evaluated in this research uses machine learning algorithms trained on large datasets of fetal ultrasound images to detect subtle growth trajectory deviations and structural patterns associated with placental insufficiency, flagging cases for closer review that might fall within a ‘borderline normal’ range on standard manual assessment. Relevance for High-Risk Pregnancy Care in Dubai Dubai’s specialist obstetric centres, including those in Dubai Healthcare City, increasingly incorporate advanced ultrasound technology into routine and high-risk antenatal care. For women identified as having risk factors for growth restriction — including hypertension, smoking history, previous growth-restricted pregnancy, or multiple pregnancy — access to the most sensitive available screening technology can provide valuable additional reassurance or earlier warning. What This Means for Your Antenatal Scans This research does not replace the fundamental importance of regular antenatal monitoring, symphysis-fundal height measurement, and clinical assessment by an experienced obstetrician. Rather, it represents a valuable complementary tool that, where available, can enhance the accuracy of an already comprehensive growth surveillance programme for at-risk pregnancies. A Note on Algorithm Diversity As with many AI-assisted diagnostic tools entering clinical practice, an important ongoing question is how these algorithms perform across genuinely diverse patient populations, including the wide range of ethnic backgrounds represented in Dubai’s pregnant population. Researchers and clinicians implementing this technology are increasingly attentive to ensuring training datasets reflect this diversity, since algorithms trained predominantly on one population can sometimes perform less reliably in others — a consideration worth raising with your obstetrician if this technology is offered as part of your care. How This Compares to Current Standard Practice in Dubai Several of Dubai’s leading fetal medicine and obstetric ultrasound centres have already begun incorporating advanced ultrasound technology into routine practice, positioning the city’s specialist obstetric care among the more technologically current internationally. Frequently Asked Questions Is AI-assisted ultrasound available for pregnancy monitoring in Dubai? Advanced ultrasound technology is increasingly available across leading UAE obstetric centres. Ask your obstetrician whether this technology is incorporated into your specific growth surveillance plan if you have risk factors for fetal growth restriction. Does AI replace the need for a specialist sonographer or obstetrician? No. AI-assisted analysis is a decision-support tool used alongside, not instead of, expert clinical interpretation by trained sonographers and obstetricians. Will AI-assisted ultrasound replace my regular growth scans? No. It is intended to enhance, not replace, the established schedule of growth scans and clinical assessment already recommended for pregnancies with risk factors for growth restriction. Conclusion Advances in ultrasound technology continue to improve how high-risk pregnancies are monitored and managed. Women in Dubai with risk factors for growth restriction should discuss the most current monitoring options available with their specialist obstetrician. Sources & References This article references recently published research and evolving guidance from peer-reviewed journals and the following recognised authorities in women’s health, current as of the time of writing: Royal College of Obstetricians and Gynaecologists (RCOG) — rcog.org.uk American College of Obstetricians and Gynecologists (ACOG) — acog.org International Federation of Gynecology and Obstetrics (FIGO) — figo.org World Health Organization (WHO) — who.int National Institute for Health and Care Excellence (NICE, UK) — nice.org.uk American Society for Reproductive Medicine (ASRM) — asrm.org European Society of Human Reproduction and Embryology (ESHRE) — eshre.eu ⚠ IMPORTANT DISCLAIMER This article is provided for general knowledge and reference purposes only and summarises recent research findings. It is not a substitute for professional medical advice, diagnosis, or treatment. No medication, treatment, or change to your healthcare should be undertaken based on this content without first consulting a qualified doctor. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Consult Dr. Ruby Rashmi Specialist Obstetrician & Gynecologist, Dubai. Benefit from evidence-based pregnancy care, advanced fetal monitoring, and personalised management for high-risk pregnancies. Contact Us

A 2025 longitudinal cohort study has added further weight to the so-called ‘timing hypothesis’ in menopause hormone therapy research, finding that women who initiated HRT within the first few years of menopause showed measurably better long-term cognitive performance in their sixties and seventies compared to women who either delayed initiation by a decade or never used HRT at all. As Dubai’s population of long-term resident women moves through midlife in increasing numbers, the quality and timeliness of menopause care available across the city’s specialist clinics has become an increasingly important marker of comprehensive women’s healthcare provision, extending well beyond simple symptom management into genuine long-term health protection. What the Timing Hypothesis Proposes The timing hypothesis suggests that the window during which hormone therapy is started relative to menopause onset significantly affects its risk-benefit balance — with initiation within the first 10 years of menopause associated with more favourable cardiovascular and, increasingly, cognitive outcomes, compared to initiation many years after menopause. What the New 2025 Research Adds This latest study followed women for over 15 years, finding that early HRT initiators scored significantly better on standardised cognitive assessments measuring memory and processing speed than late initiators or non-users, even after adjusting for education, cardiovascular risk factors, and baseline cognitive scores. Why This Matters for Women in Dubai Many women across Dubai — including the substantial professional and executive community around World Trade Centre and Jumeirah — delay addressing menopause symptoms due to busy careers, cultural reluctance to discuss menopause openly, or outdated fears about HRT safety stemming from the original, now substantially revised, 2002 Women’s Health Initiative findings. This research adds another compelling reason for women to seek timely menopause assessment rather than postponing care. What This Means in Practice This is not a recommendation that every woman must take HRT, nor that delayed initiation guarantees cognitive decline. It does, however, support a clear clinical message: women experiencing menopausal symptoms should discuss HRT with a specialist promptly rather than waiting years, since the evidence increasingly favours earlier evaluation and, where appropriate, earlier treatment. An Important Caveat It is important to add some nuance here: cognitive outcomes are influenced by an enormous range of factors beyond hormone therapy timing, including genetics, education, cardiovascular health, social engagement, and sleep quality. This research identifies a meaningful association, not a guarantee, and should be one factor among several that a woman and her specialist weigh together when considering the right time and approach to menopause care, alongside her individual symptom burden and personal risk factors. How This Compares to Current Standard Practice in Dubai Menopause care across Dubai’s specialist clinics increasingly reflects the post-Women’s Health Initiative reassessment of HRT safety, with growing comfort among both patients and clinicians in discussing early initiation. This research provides further reinforcement for that already-evolving local practice trend. Frequently Asked Questions Is it too late to start HRT if I am already 10 years past menopause? HRT may still provide symptom benefit, but the cardiovascular and now cognitive benefits associated with the timing hypothesis are most strongly observed with initiation closer to menopause onset. Discuss your individual situation with a menopause specialist. Does HRT prevent dementia? Current evidence, including this 2025 study, shows an association between earlier HRT initiation and better long-term cognitive outcomes, but HRT is not established or licensed as a dementia prevention treatment. What if I have already gone through menopause without starting HRT — is there still a benefit to starting now? HRT may still relieve current symptoms and offer bone protection benefits regardless of timing, though the specific cognitive and cardiovascular advantages associated with earlier initiation are most pronounced when started within 10 years of menopause. Conclusion Emerging cognitive health research adds further weight to the importance of timely, individualised menopause care. Women across Dubai are encouraged to discuss menopause symptoms and HRT options with a specialist as soon as they arise, rather than delaying this important conversation. Sources & References This article references recently published research and evolving guidance from peer-reviewed journals and the following recognised authorities in women’s health, current as of the time of writing: Royal College of Obstetricians and Gynaecologists (RCOG) — rcog.org.uk American College of Obstetricians and Gynecologists (ACOG) — acog.org International Federation of Gynecology and Obstetrics (FIGO) — figo.org World Health Organization (WHO) — who.int National Institute for Health and Care Excellence (NICE, UK) — nice.org.uk American Society for Reproductive Medicine (ASRM) — asrm.org European Society of Human Reproduction and Embryology (ESHRE) — eshre.eu ⚠ IMPORTANT DISCLAIMER This article is provided for general knowledge and reference purposes only and summarises recent research findings. It is not a substitute for professional medical advice, diagnosis, or treatment. No medication, treatment, or change to your healthcare should be undertaken based on this content without first consulting a qualified doctor. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Consult Dr. Ruby Rashmi Specialist Obstetrician & Gynecologist, Dubai. Receive personalised menopause care, expert HRT guidance, and evidence-based treatment tailored to your symptoms, health profile, and long-term wellbeing. Contact Us

A 2025 regional study examining vitamin D status among women with PCOS across the Gulf states has found a striking and clinically significant correlation: women with more severe vitamin D deficiency showed worse PCOS metabolic and reproductive markers, including greater insulin resistance and more irregular cycles, even after controlling for BMI. This finding adds an important layer of nuance to how PCOS is understood and managed specifically within Gulf-region healthcare settings, where the population’s unique combination of genetic background, lifestyle patterns, and environmental sun-exposure behaviour creates a distinct clinical picture that does not always mirror PCOS research conducted in other parts of the world. Why Vitamin D Deficiency Is Common in the Gulf Region Despite abundant year-round sunshine, vitamin D deficiency is paradoxically common across Gulf populations, driven by limited direct sun exposure due to clothing norms, predominantly indoor lifestyles in air-conditioned environments, and high use of sun protection. This makes the Gulf region one of the more unexpected hotspots for vitamin D deficiency globally. What the New Research Found The 2025 study found that women with PCOS and severe vitamin D deficiency (levels below 12.5 nmol/L) showed measurably higher fasting insulin and HOMA-IR scores — markers of insulin resistance — than PCOS patients with adequate vitamin D status, alongside higher rates of menstrual irregularity. The data supports a growing hypothesis that vitamin D plays a direct role in ovarian function and insulin signalling, beyond its established role in bone health. What This Means for Women in Dubai For women across Dubai managing PCOS — including those in Al Fahidi, Business Bay, and Dubai Healthcare City — this research reinforces the value of routine vitamin D testing as part of a comprehensive PCOS evaluation, not simply as a general wellness check. Correcting significant deficiency may represent a low-cost, low-risk component of a broader PCOS management plan, alongside established treatments. What to Do With This Information This research does not suggest vitamin D supplementation alone can treat PCOS, and it should not replace evidence-based first-line treatments such as lifestyle modification, metformin, or letrozole for fertility. Rather, it supports vitamin D assessment and correction as a complementary, evidence-supported addition to standard PCOS care for women found to be deficient. A Broader Question for Gulf-Region Women’s Health This research also raises an interesting broader question for Gulf-region women’s health more generally: how many other common conditions might be subtly influenced by the region’s distinctive pattern of vitamin D deficiency despite abundant sunshine? Conditions including mood disorders, autoimmune disease activity, and even certain pregnancy complications have all shown associations with vitamin D status in various studies, suggesting that routine vitamin D assessment may have value extending well beyond PCOS care alone for women living in this region. How This Compares to Current Standard Practice in Dubai Vitamin D testing is already a relatively common component of comprehensive health assessments in Dubai, given general regional awareness of deficiency prevalence. This research provides additional, specific justification for including it within PCOS-focused evaluations rather than general wellness checks alone. Frequently Asked Questions Should every woman with PCOS get her vitamin D tested? Given the regional prevalence of deficiency and this emerging evidence, vitamin D testing is a reasonable and increasingly recommended component of a comprehensive PCOS work-up, particularly for women in the Gulf region. Can vitamin D supplements cure PCOS? No. Vitamin D correction may support improved metabolic and menstrual outcomes in deficient women with PCOS, but it is a complementary measure, not a substitute for established first-line PCOS treatments. What vitamin D level is considered deficient? Levels below 25 nmol/L are generally classified as deficient, with levels below 12.5 nmol/L considered severely deficient — the threshold associated with the worst PCOS outcomes in this research. Conclusion This regionally specific research highlights why PCOS care in Dubai should account for the particular health context of the Gulf population. Dr. Ruby Rashmi incorporates vitamin D and broader metabolic assessment into every comprehensive PCOS evaluation. Sources & References This article references recently published research and evolving guidance from peer-reviewed journals and the following recognised authorities in women’s health, current as of the time of writing: Royal College of Obstetricians and Gynaecologists (RCOG) — rcog.org.uk American College of Obstetricians and Gynecologists (ACOG) — acog.org International Federation of Gynecology and Obstetrics (FIGO) — figo.org World Health Organization (WHO) — who.int National Institute for Health and Care Excellence (NICE, UK) — nice.org.uk American Society for Reproductive Medicine (ASRM) — asrm.org European Society of Human Reproduction and Embryology (ESHRE) — eshre.eu ⚠ IMPORTANT DISCLAIMER This article is provided for general knowledge and reference purposes only and summarises recent research findings. It is not a substitute for professional medical advice, diagnosis, or treatment. No medication, treatment, or change to your healthcare should be undertaken based on this content without first consulting a qualified doctor. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Consult Dr. Ruby Rashmi Specialist Obstetrician & Gynecologist, Dubai. Receive comprehensive PCOS evaluation with personalised metabolic assessment, vitamin D screening, fertility guidance, and evidence-based treatment plans. Contact Us

A 2025 multi-centre trial has provided compelling new evidence that continuous glucose monitoring (CGM) improves glycaemic control and reduces adverse outcomes in women with gestational diabetes, compared to traditional fingerstick self-monitoring. Given the notably high prevalence of gestational diabetes in the Gulf region, this research carries particular relevance for pregnant women across Dubai. As gestational diabetes prevalence across the UAE continues to sit well above global averages, technology that can genuinely improve glycaemic outcomes carries outsized importance for maternity care across the entire Emirate, not just for individual patients fortunate enough to access the newest monitoring tools. What the Study Found Women using CGM throughout their pregnancy achieved significantly more time within target glucose range compared to those using standard fingerstick monitoring, alongside reduced rates of large-for-gestational-age babies and neonatal hypoglycaemia — two of the most common complications associated with poorly controlled gestational diabetes. Why This Matters in Dubai Specifically Gestational diabetes affects an estimated 15 to 25% of pregnancies in the UAE — substantially above global averages — driven by elevated background rates of insulin resistance, obesity, and family history of type 2 diabetes among the region’s diverse population. This makes effective, accessible glucose monitoring technology particularly valuable for the large number of women managing GDM throughout the city, from Jumeirah to Downtown Dubai and beyond. How CGM Changes Day-to-Day Management Rather than requiring four to seven fingerstick tests per day, CGM provides continuous, real-time glucose data via a small sensor worn on the skin, allowing women and their care teams to identify patterns — such as specific foods or times of day associated with glucose excursions — that intermittent fingerstick testing often misses entirely. What This Means for Your Antenatal Care Women newly diagnosed with gestational diabetes in Dubai should discuss whether CGM is an appropriate option for their individual management plan. While fingerstick monitoring remains effective and is still appropriate for many women, this updated evidence supports CGM as a genuine, evidence-backed alternative for those who would benefit from more detailed glucose pattern data, particularly women requiring insulin therapy. Cost and Access Considerations Cost and access remain practical considerations alongside the clinical evidence — CGM sensors carry an ongoing cost that fingerstick testing supplies do not always match, and insurance coverage for CGM in gestational diabetes varies across providers in the UAE. Women considering this technology should discuss both the clinical benefits highlighted in this research and the practical logistics of access and cost with their obstetric team before deciding which monitoring approach best fits their pregnancy. How This Compares to Current Standard Practice in Dubai CGM technology is increasingly available across leading UAE hospitals and specialist obstetric clinics, though fingerstick monitoring remains the more universally accessible default option, particularly within standard insurance coverage frameworks across the Emirates. Frequently Asked Questions Is continuous glucose monitoring better than fingerstick testing for gestational diabetes? The 2025 research suggests CGM can provide superior glycaemic control and improved outcomes for many women, though fingerstick testing remains an effective and widely used option. The right choice depends on individual circumstances. Is CGM available for gestational diabetes management in Dubai? CGM technology is increasingly available across UAE healthcare providers. Discuss availability and suitability with your obstetrician at your antenatal consultation. Will CGM be required for all women with gestational diabetes going forward? Not necessarily. Fingerstick monitoring remains effective and appropriate for many women. CGM is an additional evidence-based option, particularly valuable for women on insulin therapy or with difficult-to-control glucose levels. Conclusion Technology continues to improve how gestational diabetes is managed and monitored. Women across Dubai facing a GDM diagnosis deserve access to the most current, evidence-based monitoring options available, tailored to their individual pregnancy. Sources & References This article references recently published research and evolving guidance from peer-reviewed journals and the following recognised authorities in women’s health, current as of the time of writing: Royal College of Obstetricians and Gynaecologists (RCOG) — rcog.org.uk American College of Obstetricians and Gynecologists (ACOG) — acog.org International Federation of Gynecology and Obstetrics (FIGO) — figo.org World Health Organization (WHO) — who.int National Institute for Health and Care Excellence (NICE, UK) — nice.org.uk American Society for Reproductive Medicine (ASRM) — asrm.org European Society of Human Reproduction and Embryology (ESHRE) — eshre.eu ⚠ IMPORTANT DISCLAIMER This article is provided for general knowledge and reference purposes only and summarises recent research findings. It is not a substitute for professional medical advice, diagnosis, or treatment. No medication, treatment, or change to your healthcare should be undertaken based on this content without first consulting a qualified doctor. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Consult Dr. Ruby Rashmi Specialist Obstetrician & Gynecologist, Dubai. Receive personalised gestational diabetes care with the latest evidence-based monitoring technologies and pregnancy management strategies. Contact Us

One of the most persistent problems in gynaecology — the average 7 to 10 year delay between symptom onset and endometriosis diagnosis — may finally be shortening. New 2025 research evaluating a non-invasive blood-based biomarker panel has shown promising sensitivity and specificity for identifying endometriosis without requiring diagnostic laparoscopy, a development with significant implications for women experiencing chronic pelvic pain across Dubai. Given that endometriosis is now understood to affect roughly one in ten women of reproductive age globally, the scale of this diagnostic delay problem is substantial — and any genuine advance toward faster, less invasive diagnosis carries significant implications for the many women across Dubai’s diverse communities currently living with undiagnosed or recently diagnosed disease. Why Endometriosis Diagnosis Has Been So Difficult Endometriosis has historically required laparoscopic surgery with histological confirmation for definitive diagnosis. This surgical requirement, combined with the normalisation of severe period pain in many cultures and healthcare settings, has driven the well-documented multi-year diagnostic delay that defines this condition globally. What the New Research Shows The 2025 study evaluated a panel of inflammatory and hormonal blood biomarkers in women with clinically suspected endometriosis, finding sensitivity and specificity rates that, while not yet matching laparoscopic-histological confirmation, were sufficiently strong to support its use as a triage tool — helping identify which women should be prioritised for specialist referral and, where appropriate, surgical confirmation. What This Means for Women in Dubai For women across Mankhool, BurJuman, and Dubai Healthcare City experiencing the hallmark symptoms of endometriosis — progressively worsening period pain, deep pain during intercourse, painful bowel movements during menstruation, or unexplained infertility — this development offers hope for a faster path to diagnosis and treatment, without necessarily requiring immediate surgical intervention to begin appropriate hormonal management. Current Best Practice While This Research Develops It is important to note that this biomarker panel is not yet validated for standalone diagnostic use in routine clinical practice. Current ESHRE 2022 guidelines already support empirical hormonal treatment based on clinical symptoms and ultrasound findings without mandatory laparoscopy in many cases — meaning women experiencing significant dysmenorrhoea or pelvic pain consistent with endometriosis do not need to wait for this biomarker test to become available before starting appropriate evidence-based treatment. Putting This Research Into Context It is also worth noting that the broader diagnostic delay in endometriosis is not purely a technological problem — it is equally a cultural and educational one, rooted in decades of normalising severe menstrual pain as something to simply endure. Even as biomarker testing and other diagnostic tools continue to improve, the most immediate, accessible step toward reducing diagnostic delay remains straightforward: women experiencing pain severe enough to affect daily function should feel confident seeking specialist assessment promptly, rather than waiting to see if it resolves on its own. How This Compares to Current Standard Practice in Dubai Dubai’s gynaecology practices generally follow the established ESHRE pathway of empirical hormonal treatment based on clinical assessment, with laparoscopy reserved for specific indications. This approach already reduces unnecessary diagnostic delay independent of any future biomarker test becoming available. Frequently Asked Questions Can I get diagnosed with endometriosis without surgery? In many cases, yes. Current international guidelines support starting hormonal treatment based on clinical symptoms and ultrasound findings alone, reserving laparoscopy for cases requiring definitive diagnosis or surgical management. Is the new endometriosis blood test available in Dubai yet? As of 2025, this biomarker panel remains primarily a research tool rather than a widely available clinical test. Ask your specialist about the most current evidence-based diagnostic pathway available to you. Should I ask my doctor specifically about this blood biomarker test? It is reasonable to ask, though be aware this test is still primarily used in research settings rather than as a routine, widely available clinical test as of 2025. Conclusion Reducing the endometriosis diagnostic delay is one of gynaecology’s most important ongoing challenges. Women in Dubai experiencing severe period pain should not wait years for answers — Dr. Ruby Rashmi evaluates suspected endometriosis using the most current evidence-based pathways available today. Sources & References This article references recently published research and evolving guidance from peer-reviewed journals and the following recognised authorities in women’s health, current as of the time of writing: Royal College of Obstetricians and Gynaecologists (RCOG) — rcog.org.uk American College of Obstetricians and Gynecologists (ACOG) — acog.org International Federation of Gynecology and Obstetrics (FIGO) — figo.org World Health Organization (WHO) — who.int National Institute for Health and Care Excellence (NICE, UK) — nice.org.uk American Society for Reproductive Medicine (ASRM) — asrm.org European Society of Human Reproduction and Embryology (ESHRE) — eshre.eu ⚠ IMPORTANT DISCLAIMER This article is provided for general knowledge and reference purposes only and summarises recent research findings. It is not a substitute for professional medical advice, diagnosis, or treatment. No medication, treatment, or change to your healthcare should be undertaken based on this content without first consulting a qualified doctor. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Consult Dr. Ruby Rashmi Specialist Obstetrician & Gynecologist, Dubai. Receive expert evaluation and evidence-based care for endometriosis, chronic pelvic pain, fertility concerns, and women’s health conditions. Contact Us

New clinical trial data released in 2025 has strengthened the evidence base for GLP-1 receptor agonists — the class of medication that includes semaglutide and liraglutide — as an effective adjunct treatment for weight management and metabolic improvement in women with PCOS. While not yet formally licensed specifically for PCOS, the off-label evidence is mounting rapidly. As one of the fastest-growing areas of metabolic medicine, GLP-1 therapy has moved rapidly from a diabetes-specific treatment to a broader metabolic health tool, and its application to PCOS specifically reflects this wider trend — one that specialist clinics across Dubai, from Al Seef to Dubai Design District, are actively incorporating into individualised patient care plans as the evidence matures. What the New Data Shows The 2025 trial data demonstrated that women with PCOS and a BMI over 27 treated with GLP-1 receptor agonists achieved significantly greater weight loss than those receiving lifestyle intervention alone, alongside measurable improvements in insulin sensitivity, menstrual regularity, and androgen levels — the core metabolic and reproductive features of PCOS. Why Weight Management Matters So Much in PCOS Insulin resistance affects an estimated 65–80% of women with PCOS regardless of body weight, and even modest weight loss of 5–10% can restore ovulation in over half of overweight women with the condition. For women struggling with the well-documented difficulty of weight loss in PCOS — driven by the condition’s own metabolic effects — these medications represent a genuinely new therapeutic option beyond traditional lifestyle and metformin-based approaches. Relevance for Women in Dubai Given the elevated background prevalence of insulin resistance and metabolic syndrome features in several of the ethnic groups that make up Dubai’s population, PCOS-related weight management is a particularly common and often particularly challenging clinical concern for women across the city, from Al Seef to Dubai Design District and beyond. Access to evidence-based, individually tailored weight management options — used appropriately and under specialist supervision — is an important addition to the overall PCOS treatment toolkit. Important Caveats These medications are not appropriate for every woman with PCOS, are not licensed as fertility treatments, and must be discontinued well in advance of attempting conception due to limited safety data in pregnancy. Any consideration of GLP-1 therapy for PCOS should occur within a comprehensive, specialist-led management plan — not as a standalone or first-line intervention. Putting This Research Into Context Specialists are also watching closely for longer-term data on metabolic improvements following discontinuation of GLP-1 therapy, since one open question in this still-developing field is whether the insulin sensitivity and androgen improvements seen during treatment are sustained afterward, or whether they require ongoing medication to maintain. Until more long-term data is available, these medications are best considered one tool within an ongoing, comprehensive PCOS management relationship rather than a finite treatment course. How This Compares to Current Standard Practice in Dubai GLP-1 medications are increasingly prescribed off-label for weight management across UAE clinics, including for appropriately selected women with PCOS, though this remains an individualised decision made between patient and specialist rather than a routine, automatic recommendation for every overweight PCOS patient. Frequently Asked Questions Can I take semaglutide for PCOS while trying to conceive? No. GLP-1 receptor agonists should be discontinued well before attempting conception due to insufficient pregnancy safety data. Discuss timing carefully with your specialist. Is GLP-1 therapy a first-line treatment for PCOS weight management? No. Lifestyle modification remains first-line. GLP-1 therapy is considered as an adjunct for appropriately selected women who have not achieved sufficient results with lifestyle measures alone. Are GLP-1 medications covered by health insurance in Dubai for PCOS? Coverage varies significantly between insurance providers and depends on the specific indication for which the medication is prescribed. Check with your insurer and clinic regarding current coverage policies. Conclusion Emerging metabolic therapies are expanding what is possible in PCOS management. Women in Dubai exploring weight management options for PCOS should do so within a comprehensive specialist care plan that weighs the latest evidence against their individual fertility goals and health profile. Sources & References This article references recently published research and evolving guidance from peer-reviewed journals and the following recognised authorities in women’s health, current as of the time of writing: Royal College of Obstetricians and Gynaecologists (RCOG) — rcog.org.uk American College of Obstetricians and Gynecologists (ACOG) — acog.org International Federation of Gynecology and Obstetrics (FIGO) — figo.org World Health Organization (WHO) — who.int National Institute for Health and Care Excellence (NICE, UK) — nice.org.uk American Society for Reproductive Medicine (ASRM) — asrm.org European Society of Human Reproduction and Embryology (ESHRE) — eshre.eu ⚠ IMPORTANT DISCLAIMER This article is provided for general knowledge and reference purposes only and summarises recent research findings. It is not a substitute for professional medical advice, diagnosis, or treatment. No medication, treatment, or change to your healthcare should be undertaken based on this content without first consulting a qualified doctor. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Consult Dr. Ruby Rashmi Specialist Obstetrician & Gynecologist, Dubai. Get personalised, evidence-based PCOS care and expert guidance on weight management, fertility planning, and the latest metabolic treatment options. Contact Us

A 2025 prospective cohort study has provided some of the strongest evidence yet that an imbalanced vaginal microbiome — specifically, reduced Lactobacillus dominance — is independently associated with increased risk of recurrent miscarriage, even after adjusting for known risk factors such as maternal age and chromosomal abnormality. This adds an important new dimension to recurrent pregnancy loss investigation. For the many women across Dubai who have experienced the particular grief and uncertainty of unexplained recurrent pregnancy loss, often after exhaustive and inconclusive standard testing, this kind of emerging research offers something valuable beyond its immediate clinical application: a sense that the medical community continues actively searching for answers on their behalf. What the Study Found Researchers found that women with a Lactobacillus-dominant vaginal microbiome had significantly lower rates of early pregnancy loss compared to those with a more diverse, less Lactobacillus-dominant microbial profile. The proposed mechanism involves a less protective local immune and inflammatory environment in the absence of Lactobacillus dominance, potentially affecting implantation and early placental development. How This Fits Into Existing Recurrent Miscarriage Evaluation Recurrent miscarriage — defined as two or more consecutive pregnancy losses — already involves a structured evaluation covering chromosomal analysis, antiphospholipid antibody testing, thyroid function, uterine anatomy assessment, and parental karyotyping where indicated. This research suggests vaginal microbiome assessment may become a meaningful addition to that evaluation pathway, particularly for women in whom standard investigations return no clear cause — a group that represents up to 50% of recurrent miscarriage cases. Relevance for Women in Dubai Recurrent pregnancy loss is a deeply distressing experience, and for the substantial proportion of women in Dubai for whom no cause is identified through standard testing, this research offers a potential new avenue for both explanation and, eventually, targeted intervention such as vaginal probiotic therapy — though it should be noted that probiotic treatment trials are still in early stages and not yet part of routine clinical guidance. What to Expect From a Specialist Evaluation Today While vaginal microbiome testing is not yet a standard part of every recurrent miscarriage work-up, women undergoing investigation in Dubai should expect a comprehensive evaluation covering all currently established causes, with their specialist remaining alert to emerging research such as this as the evidence base continues to develop. Putting This Research Into Context It is also worth placing this finding within the broader context of recurrent miscarriage research, which has expanded considerably over the past decade to include immunological, metabolic, and now microbiomic factors alongside the traditional anatomical and genetic causes. For many women, recurrent pregnancy loss investigation can feel like a process of ruling things out one by one without ever finding a definitive answer — and while this microbiome research does not yet provide a treatment pathway, it does offer a scientifically grounded explanation that may eventually translate into one. How This Compares to Current Standard Practice in Dubai Recurrent miscarriage evaluation in Dubai’s specialist clinics typically follows established international protocols covering genetic, anatomical, hormonal, and autoimmune assessment. Microbiome testing has not yet been incorporated into routine local practice, consistent with its status as an emerging rather than established area of investigation globally. Frequently Asked Questions Should I get my vaginal microbiome tested if I’ve had recurrent miscarriages? This is an emerging area of research rather than a standard clinical test at this stage. Discuss your full investigation options with a fertility specialist experienced in recurrent pregnancy loss. Can probiotics prevent miscarriage? Current evidence is preliminary. While the association between microbiome balance and miscarriage risk is increasingly clear, controlled trials of probiotic treatment for miscarriage prevention are still ongoing. Does this mean all recurrent miscarriage is caused by microbiome imbalance? No. This research identifies one additional contributing factor among many recognised causes of recurrent pregnancy loss, including chromosomal, anatomical, hormonal, and autoimmune factors. A full evaluation remains essential. Conclusion Recurrent miscarriage investigation continues to evolve as research uncovers new contributing factors. Women in Dubai facing this difficult experience deserve a thorough, current evaluation from a specialist engaged with the latest evidence, alongside compassionate emotional support throughout. Sources & References This article references recently published research and evolving guidance from peer-reviewed journals and the following recognised authorities in women’s health, current as of the time of writing: Royal College of Obstetricians and Gynaecologists (RCOG) — rcog.org.uk American College of Obstetricians and Gynecologists (ACOG) — acog.org International Federation of Gynecology and Obstetrics (FIGO) — figo.org World Health Organization (WHO) — who.int National Institute for Health and Care Excellence (NICE, UK) — nice.org.uk American Society for Reproductive Medicine (ASRM) — asrm.org European Society of Human Reproduction and Embryology (ESHRE) — eshre.eu ⚠ IMPORTANT DISCLAIMER This article is provided for general knowledge and reference purposes only and summarises recent research findings. It is not a substitute for professional medical advice, diagnosis, or treatment. No medication, treatment, or change to your healthcare should be undertaken based on this content without first consulting a qualified doctor. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Consult Dr. Ruby Rashmi Specialist Obstetrician & Gynecologist, Dubai. Receive compassionate, evidence-based evaluation and personalised care for recurrent pregnancy loss and fertility concerns. Contact Us

New research published in 2025 has demonstrated that offering HPV self-sampling kits as an alternative to clinician-collected cervical screening increases overall screening participation by approximately 30%, with the greatest improvement seen among women who had never previously attended for cervical screening. For Dubai’s diverse population, where cultural and modesty considerations sometimes affect screening uptake, this represents a meaningful step forward. This shift matters enormously for a city like Dubai, where women from dozens of different cultural backgrounds — each with their own relationship to medical examination, modesty, and healthcare-seeking behaviour — make up the patient population of nearly every gynaecology clinic in the city, from Bur Dubai to Jumeirah. How HPV Self-Sampling Works Self-sampling allows a woman to collect her own vaginal swab using a simple kit, either at home or in a private clinic room, rather than undergoing a clinician-performed speculum examination. The sample is then tested in a laboratory for high-risk HPV using the same molecular testing methods used for clinician-collected samples. If HPV is detected, the woman is invited for follow-up cytology and, if needed, colposcopy. Why This Matters for Women in Dubai Several studies, including the 2025 research informing this update, have specifically identified modesty concerns, time constraints, and anxiety about pelvic examination as key barriers to cervical screening — barriers that resonate strongly within parts of Dubai’s diverse community, including women from South Asian, Arab, and East Asian backgrounds. Self-sampling removes the most significant barrier for many women: the examination itself. Accuracy Compared to Clinician Sampling Critically, the research confirms that self-collected samples show comparable sensitivity to clinician-collected samples for detecting high-risk HPV, when using validated, WHO-endorsed self-sampling devices and PCR-based testing methods. This addresses the previous concern that self-sampling might compromise accuracy. What This Means Going Forward Women in Bur Dubai, Al Fahidi, and Jumeirah who have delayed cervical screening due to discomfort or modesty concerns now have a credible, evidence-based alternative pathway into the screening system. It is important to understand that a positive HPV self-test still requires a follow-up clinical visit — self-sampling identifies risk, it does not replace clinical assessment and treatment when needed. Putting This Research Into Context Beyond the screening uptake data itself, this research has prompted broader conversations within women’s health services about removing other access barriers — including extended clinic hours, multilingual support materials, and private, unhurried consultation environments. Dubai’s clinics serving a genuinely multicultural patient base have a particular opportunity to apply these lessons, recognising that the barriers to screening are rarely about a lack of awareness alone, and far more often about the practical and emotional experience of attending. How This Compares to Current Standard Practice in Dubai Cervical screening practice across Dubai’s healthcare providers has traditionally relied on clinician-collected samples, consistent with most international settings. As self-sampling evidence continues to strengthen, it is reasonable to expect gradual adoption across more clinics, though widespread availability may take time to roll out fully across the city. Frequently Asked Questions Is HPV self-sampling as accurate as a doctor-performed Pap smear? Validated self-sampling devices combined with PCR-based HPV testing show comparable sensitivity to clinician-collected samples for high-risk HPV detection, according to the 2025 research. What happens if my HPV self-test comes back positive? A positive result requires a follow-up clinical visit for cytology and, where indicated, colposcopy. Self-sampling identifies risk but does not replace clinical follow-up. Can I request a self-sampling kit instead of a clinic visit in Dubai? Availability varies by provider. Ask your gynaecologist or clinic directly whether self-sampling kits are offered as part of their cervical screening pathway. Conclusion Removing barriers to cervical screening saves lives. Dr. Ruby Rashmi’s Dubai practice stays current with these emerging screening innovations, helping more women across the city access the preventive care they need, in whatever format makes that care most achievable for them. Sources & References This article references recently published research and evolving guidance from peer-reviewed journals and the following recognised authorities in women’s health, current as of the time of writing: Royal College of Obstetricians and Gynaecologists (RCOG) — rcog.org.uk American College of Obstetricians and Gynecologists (ACOG) — acog.org International Federation of Gynecology and Obstetrics (FIGO) — figo.org World Health Organization (WHO) — who.int National Institute for Health and Care Excellence (NICE, UK) — nice.org.uk American Society for Reproductive Medicine (ASRM) — asrm.org European Society of Human Reproduction and Embryology (ESHRE) — eshre.eu ⚠ IMPORTANT DISCLAIMER This article is provided for general knowledge and reference purposes only and summarises recent research findings. It is not a substitute for professional medical advice, diagnosis, or treatment. No medication, treatment, or change to your healthcare should be undertaken based on this content without first consulting a qualified doctor. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Consult Dr. Ruby Rashmi Specialist Obstetrician & Gynecologist, Dubai. Stay ahead with the latest cervical screening innovations and receive personalised, evidence-based preventive care. Contact Us